US Pat. No. 10,167,407

AQUEOUS POLYMER DISPERSION FOR PAPER WITH A COPOLYMER OF VINYL ACETATE AND AN ACRYLATE MONOMER PREPARED IN THE PRESENCE OF A STARCH DERIVATIVE

BASF SE, Ludwigshafen (D...

1. A process for preparing an aqueous dispersion comprising a polymer P, the process comprising:emulsifying a mixture comprising monomers in an aqueous medium, and
polymerizing the monomers in the presence of a free-radical initiator and a starch derivative,
wherein the mixture consists of:
vinyl acetate, as a monomer (a),
at least one acrylate monomer, which is at least one selected from the group consisting of a C1-C10 alkyl acrylate and a C1-C10 alkyl methacrylate, as a monomer (b),
at least one ?,?-ethylenically unsaturated C3-C6 carboxylic acid, as a monomer (c),
at least one monomer selected from the group consisting of glycidyl methacrylate, glycidyl acrylate, allyl methacrylate and allyl acrylate, as a monomer (d),
optionally at least one ethylenically unsaturated sulfonic acid, as a monomer (e), and
optionally at least one ethylenically unsaturated other monomer, which is
different from the monomers (a), (b), (c), (d) and (e), as a monomer (f), and wherein
the content of the vinyl acetate monomer (a) is from 70 to 94.7 parts by weight of the monomers,
the content of the at least one acrylate monomer (b) is from 5 to 25 parts by weight of the monomers,
the content of the at least one ?,?-ethylenically unsaturated C3-C6 carboxylic acid monomer (c) is from 0.1 to 10 parts by weight of the monomers,
the content of the at least one monomer (d) selected from the group consisting of glycidyl methacrylate, glycidyl acrylate, allyl methacrylate and allyl acrylate is from 0.1 to 10 parts by weight of the monomers,
the optional content of the at least one ethylenically unsaturated sulfonic acid monomer (e) is from 0.1 to 5 parts by weight of the monomers,
the optional content of the at least one other ethylenically unsaturated monomer (f) is from 0.1 to 15 parts by weight of the monomers, and
the sum total of the parts by weight of the monomers (a), (b), (c), (d), (e) and (f) is 100.
US Pat. No. 10,167,199

METHOD FOR MANUFACTURING HIGHLY PURE SILICON, HIGHLY PURE SILICON OBTAINED BY THIS METHOD, AND SILICON RAW MATERIAL FOR MANUFACTURING HIGHLY PURE SILICON

Silicio Ferrosolar S.L., ...

1. A method for producing high purity silicon characterised in that it is a method of high purity silicon production that produces high purity silicon by unidirectional solidification of raw material molten silicon in a molding vessel, and uses as said raw material molten silicon that has a carbon concentration of 100˜1000 ppmw, and a germanium concentration of 50-1000 ppmw wherein a heat extraction process drives said unidirectional solidification forward, a preservation process is provided to preserve the molten state of the molten silicon in the molding vessel and by this preservation process, a silicon carbide contact layer of 20 ?m thickness or more is formed on the surface of the inner wall of the molding vessel.
US Pat. No. 10,167,457

NUCLEOBASE EDITORS AND USES THEREOF

President and Fellows of ...

1. A fusion protein comprising:(i) a Cas9 domain, wherein the Cas9 domain when in conjunction with a bound guide RNA (gRNA) specifically binds to a target nucleic acid sequence;
(ii) a cytidine deaminase domain, wherein the cytidine deaminase domain deaminates a cytosine base in a single-stranded portion of the target nucleic acid sequence when in conjunction with the Cas9 domain and the gRNA; and
(iii) an uracil glycosylase inhibitor (UGI) domain, wherein the UGI domain inhibits a uracil-DNA glycosylase.
US Pat. No. 10,167,222

SELENIUM-FREE SUNGLASS MATERIAL WITH BROWN TINT

Corning Incorporated, Co...

1. A glass comprising B2O3, SiO2, and Fe, said Fe including ferric ion (Fe3+) and ferrous ion (Fe2+), said glass lacking Se and having (i) a tint with a chromaticity coordinate x in the range from 0.37-0.65, and (ii) a concentration of said ferrous ion (Fe2+) sufficient to provide an average percent transmittance (% T) over the wavelength range from 780 nm-2000 nm, for a thickness of 1.9 mm, of less than 3%.
US Pat. No. 10,166,210

METHODS OF SUBTYPING CRC AND THEIR ASSOCIATION WITH TREATMENT OF COLON CANCER PATIENTS WITH OXALIPLATIN

NSABP Foundation, Inc., ...

1. A method of treating stage III colon cancer patients comprising:a) obtaining a colon cancer tumor tissue sample from a patient with stage III colon cancer,
b) contacting a genetic sample from said colon cancer tumor tissue sample with a plurality of specific genetic sequence binding targets and measuring the expression level of a panel of 72 genes, wherein the 72 genes are AKAP12, ANKRD44, BGN, BHLHE41, BMP7 C8orf84, CAB39L, CDKN2B, CKMT2, COL11A1, COMP, CPE, CSGALNACT1, CXCL10, CXCL11, CXCL13, CXCL2, CXCL9, CYP1B1, DAPK1, DCBLD2, DPEP1, EPB41L4B, ERAP2, F5, FAP, FGL2, FN1, FNDC1, GBP1, GBP4, GPX3, GRM8, GZMB, HGD, HOXA13, HSD17B2, ID4, IDO1, IL8, INHBA, MFAP5, MGP, MMP11, MMP28, NFIB, OAS2, PAPPA, PIGR, PLA2G12B, POU2AF1, PRAP1, PROM2, PSMB9, PTPRC, ROBO1, SDC2, SELL, SERPINE1, SFRP2, SGK2, SLC4A4, SPARC, SPP1, SSPN, STC1, TACSTD2, TGFBR3, TM4SF1, TYMS, VCAN, and VNN1,
c) obtaining a gene expression signature for said colon cancer tumor tissue from the gene expression level of the panel of 72 genes in b),
d) identifying said colon cancer tumor tissue as being a subtype responsive to oxaliplatin, and
e) administering oxaliplatin in combination with 5?fluorouracil and leucovorin (FULV) to said patient with Stage III colon cancer in a).
US Pat. No. 10,166,256

ANTI-TUMOR T CELL IMMUNITY INDUCED BY HIGH DOSE RADIATION

The Board of Trustees of ...

1. A method for treating a cancer in a subject, the method comprising:a. activating T cells with a high dose of localized radiation at a tumor site;
b. collecting a population of cells comprising the activated T cells; and
c. administering the collected population of cells to the subject, thereby treating the cancer.
US Pat. No. 10,166,259

ISOLATION OF EXOSOMES FROM COLOSTRUM POWDER AND EXOSOMAL DRUG FORMULATIONS USING THE SAME

3P Biotechnologies, Inc.,...

1. A method for isolation of purified exosomes from colostrum powder, the method comprising:a. providing a sample of either standardized bovine colostrum powder or standardized caprine colostrum powder;
b. suspending the colostrum powder in water and agitating to produce a uniform suspension;
c. subjecting the colostrum powder suspension to centrifugation at a first predetermined G-force to produce a first supernatant and collecting the first supernatant;
d. subjecting the first supernatant from step (c) to centrifugation at a second predetermined G-force to produce a second supernatant and collecting the second supernatant;
e. subjecting the second supernatant from step (d) to centrifugation at a third predetermined G-force to produce an exosomal pellet and collecting the exosomal pellet;
f. washing the exosomal pellet in de-ionized water; and,
g. suspending the exosomal pellet which contains the isolated purified exosomes in phosphate-buffered-saline (PBS), wherein the purified exosome yield is at least 8-times greater than if the exosomes were isolated from milk.
US Pat. No. 10,165,748

MAIZE INBRED PH42AN

PIONEER HI-BRED INTERNATO...

1. A seed, plant, plant part, or plant cell of inbred maize variety PH42AN, representative seed of the variety having been deposited under ATCC accession number PTA-124771.
US Pat. No. 10,166,260

WOUND CARE PRODUCT WITH EGG SHELL MEMBRANE

Blaine Laboratories, Inc....

1. A wound care gel, comprising:a) irradiated egg shell membrane comprising protein, wherein said irradiated egg shell membrane is present in an amount of about 0.1 to about 10% by weight;
b) an antimicrobial compound in an amount of about 0.001 to about 0.1% by weight;
c) an effective amount of a tissue growth accelerator; and optionally
d) inactive ingredients;
wherein said wound care gel is obtained by:
i. mixing the irradiated eggshell membrane with an aqueous phase to provide a protein solution;
ii. partially neutralizing the protein solution by adding carbomer to provide a partially neutralized protein gel;
iii. optionally adding glycerin to the partially neutralized protein gel;
iv. adding triethanolamine to the partially neutralized protein gel of step ii) or step iii) to provide a neutralized gel;
v. adding the antimicrobial compound to the neutralized gel;
vi. adding the tissue growth accelerator; and optionally
vii. adding inactive ingredients.
US Pat. No. 10,166,262

STRAIN OF BACTERIA AND COMPOSITION COMPRISING THE SAME

1. A composition comprising a strain of Lactobacillus plantarum AMT 14 bacteria (PCM Accession No. B/00092) in an amount of 101 to 1013 of colony forming units cfu/ml, a medium, and a bulking agent.
US Pat. No. 10,165,752

MAIZE INBRED PH2RTF

PIONEER HI-BRED INTERNATI...

1. A seed, plant, plant part, or plant cell of inbred maize variety PH2RTF, representative seed of the variety having been deposited under ATCC accession number PTA-124800.
US Pat. No. 10,166,520

CATCAPSULES FOR SELF-HEALING APPLICATIONS

International Business Ma...

1. A method of making a linked microcapsule, comprising:providing a first microcapsule having a first payload agent inside the first microcapsule and a first orthogonal-functionalized unit incorporated into a wall of the first microcapsule;
providing a second microcapsule having a second payload agent inside the second microcapsule and a second orthogonal-functionalized unit incorporated into a wall of the second microcapsule; and
forming a linked microcapsule by reacting:
(a) the first microcapsule with the second microcapsule in an acyclic diene metathesis reaction,
(b) the first microcapsule with the second microcapsule in a thiol-ene click reaction,
(c) the first microcapsule with the second microcapsule in a thiol-yne click reaction,
(d) the first microcapsule with the second microcapsule in a thiol-epoxy click reaction,
(e) the first microcapsule with the second microcapsule in a Michael reaction, or
(f) a mixture of an isocyanate, the first microcapsule, and the second microcapsule.
US Pat. No. 10,166,265

PHARMACEUTICAL COMPOSITION FOR TREATING BACTERIAL AND VIRAL INFECTIONS

1. A pharmaceutical composition comprising an amount of vitamin C, zinc, vitamin A, vitamin D3, vitamin B6, garlic and Echinacea effective to treat bacterial and/or viral infections.
US Pat. No. 10,166,266

PROCESS TO ENHANCE THE BIOACTIVITY OF ASHWAGANDHA EXTRACTS

1. A method of treating stress comprising administering an enteric coated composition to a subject in need thereof, the enteric coated composition comprising extract of Withania somnifera and an enteric coating material, wherein the extract of Withania somnifera comprises by weight:at least about 3.5% withanolide glycosides,
less than about 0.1% withanolide aglycones,
less than about 0.1% alkaloids, and,
less than about 0.1% oligosaccharides,
and wherein the enteric coating material is selected from the group consisting of poly (methacrylic acid-co-methyl methacrylate), and, a combination of modified ethyl cellulose and sodium alginate.
US Pat. No. 10,166,267

MULTI-COMPONENT FORMULATIONS FOR THE TREATMENT OF COGNITIVE DECLINE INCLUDING ALZHEIMER'S DISEASE

1. A multi-component formulation comprising:about 0.01% to about 5% by weight methylsulfonylmethane,
about 5% to about 99% by weight fructose 1,6-diphosphate, and
about 0.01% to about 95% by weight of at least one of an herbal component or a nutritional component comprising curcumin.
US Pat. No. 10,168,321

COMPOSITION COMPRISING UP-CONVERTING PHOSPHORS FOR DETECTING AN ANALYTE

Roche Diabetes Care, Inc....

1. A detector matrix for detecting at least one analyte in a sample comprising (i) at least one enzyme active in the presence of said at least one analyte and (ii) at least one indicator reagent changing at least one optical property dependent on the activity of said enzyme, wherein the indicator reagent is homogenously distributed within said detector matrix, wherein said detector matrix further comprises (iii) UV-emitting up-converting phosphor particles.
US Pat. No. 10,166,273

SYNERGISTIC TUMOR TREATMENT WITH ANTIBODIES TARGETING PD-1, PD-L1 OR CTLA4 AND INTEGRIN-BINDING-FC-FUSION PROTEIN

The Board of Trustees of ...

1. A method for inhibiting growth and/or proliferation of tumor cells in a subject comprising administering to the subject an effective amount of an integrin-binding-Fc fusion protein, wherein the integrin-binding-Fc fusion protein comprises (i) an integrin-binding polypeptide comprising an integrin-binding loop and a knottin polypeptide scaffold; and (ii) an immunoglobulin Fc domain, wherein the integrin-binding polypeptide is operably linked to the Fc domain, and an immune checkpoint blocker selected from the group consisting of an antibody or antibody fragment targeting PD-1, an antibody or antibody fragment targeting PD-L1, and an antibody or antibody fragment targeting CTLA4.
US Pat. No. 10,168,322

ELECTRONIC ANALYTE ASSAYING DEVICE

1. A diagnostic device for detecting the presence of an analyte in a fluid sample, the device comprising:a housing configured to receive a lateral flow diagnostic strip, said lateral flow diagnostic strip including:
a receiving end for receiving the fluid sample;
a terminal end opposite said receiving end; and
a capture region located between said receiving end and said terminal end; and a processor configured to, upon receiving the fluid sample:
illuminate the lateral flow diagnostic strip;
measure intensity values of light reflected from the lateral flow diagnostic strip;
obtain, during a first time period, a first series of intensity value pairs, wherein each intensity value pair of the first series of intensity value pairs comprises a measurement signal and a background signal, and wherein the measurement signal and the background signal for each intensity value pair of the first series of intensity value pairs are obtained at substantially the same time;
calculate the intensity difference between the measurement signal and the background signal for each pair of the first series of intensity value pairs to generate a first series of intensity difference values;
generate, at the end of the first time period, a fluid front detection result based at least in part on the first series of intensity difference values, wherein the fluid front detection result indicates whether at least a portion of the first series of intensity difference values correspond to a threshold for identifying a fluid front;
obtain, during a second time period, a second series of intensity value pairs, wherein each intensity value pair of the second series of intensity value pairs comprises a measurement signal and a background signal, and wherein the measurement signal and the background signal for each intensity value pair of the second series of intensity value pairs are obtained at substantially the same time;
calculate the intensity difference between the measurement signal and the background signal for each pair of the second series of intensity value pairs to generate a second series of intensity difference values; and
generate, at the end of the second time period, a message indicating that the analyte is present in the fluid sample based at least in part on:
(i) the fluid front detection result generated with the first series of intensity difference values obtained during the first time period, and
(ii) the second series of intensity difference values obtained during the second time period.
US Pat. No. 10,166,275

ANTIMICROBIAL COMPOSITION COMPRISING PYROGENIC SILICA AND SERRATHIOPEPTIDASE AND USES THEREOF

Willingsford Limited., S...

1. An antimicrobial composition comprising from 90 to 99% by weight a silicious absorbent made of globules of fine hydrated pyrogenic silica and polysilicic acid (SiO2*H2O); and the remainder by weight, comprising 1 to 10% serrathiopeptidase immobilized thereon; wherein said antimicrobial composition is a dry powder.
US Pat. No. 10,166,276

COMPOSITIONS AND METHODS FOR TREATMENT OF NON-HODGKINS LYMPHOMA

The Trustees of the Unive...

1. A method of inducing an immune response against a B cell lymphoma in a subject, comprising administering a pharmaceutical composition comprising a fusion polypeptide comprising a fragment of a listeriolysin O (LLO) protein and an antigen, wherein said fragment of an LLO protein is chemically conjugated to said antigen, wherein said antigen is a fragment of a B cell receptor (BCR) comprising the idiotype of said BCR, and wherein said fragment of an LLO protein is an N-terminal fragment comprising the amino acid sequence set forth in SEQ ID NO: 25 or an N-terminal LLO-detox fragment comprising the amino acid sequence set forth in SEQ ID NO: 41.
US Pat. No. 10,167,301

PROCESS FOR THE PREPARATION OF BIS(CHLOROMETHYL)DICHLOROSILANE AND BIS(CHLOROMETHYL)(ARYL)CHLOROSILANE

Dow Global Technologies L...

1. A process for the preparation of bis(chloromethyl)dichlorosilane comprising reacting bis(chloromethyl)diarylsilane and one or more chloride compounds in the presence of one or more Lewis acids in an inert solvent and under an inert atmosphere.
US Pat. No. 10,168,326

INTERFERENCE-SUPPRESSED IMMUNOASSAY TO DETECT ANTI-DRUG ANTIBODIES IN SERUM SAMPLES

F. HOFFMANN-LA ROCHE INC....

1. An interference-suppressed immunoassay for the detection of anti-drug antibodies against a drug antibody for the treatment of rheumatoid arthritis, juvenile arthritis, or osteoarthritis, said method comprising:(a) incubating a sample from a rheumatoid arthritis, juvenile arthritis, or osteoarthritis patient treated with said drug antibody simultaneously with a mixture comprising 0.5 ?g/ml to 10 ?g/ml of a 1:1 conjugate of said drug antibody to a first member of a binding pair via a single lysine residue as a capture drug antibody and 0.5 ?g/ml to 10 ?g/ml of a 1:1 conjugate of said drug antibody to a detectable label via a single lysine residue as a tracer drug antibody for 0.5 to 24 hours to generate a capture drug antibody/anti-drug antibody/tracer drug antibody complex, wherein the sample comprises 1% to 20% serum and is supplemented with oligomeric human IgG prior to the incubation to a final concentration of 10 ?g/ml to 1000 ?g/ml,
(b) immobilizing the capture drug antibody/anti-drug antibody/tracer drug antibody complex formed in step (a) on a solid phase by covalently or non-covalently conjugating said first member of a binding pair to a second member of a binding pair on the solid phase,
(c) incubating the immobilized complex with an antibody against the detectable label of the tracer drug antibody, conjugated to a second detectable label, and
(d) detecting the anti-drug antibodies against said drug antibody via a signal of the detectable label of the antibody of step (c), and
wherein the drug antibody is an anti-inflammatory antibody.
US Pat. No. 10,166,534

METHOD FOR REDUCTION OF ORGANIC MOLECULES

RHEINISCH-WESTFALISCHE TE...

10. The method according to claim 7, wherein the sulfonic acid is selected from the group consisting of methanesulfonic acid, trifluoromethanesulfonic acid, p-toluenesulfonic acid, p-bromobenzosulfonic acid, p-nitrobenzosulfonic acid, sulfuric acid, hydrochloric acid, hydrofluoric acid, trifluoroacetic acid, perchloric acid, bis(trifluoromethane)sulfonimide and mixtures thereof.
US Pat. No. 10,167,306

CRYSTALLINE FORM OF 1-(BETA-D-GLUCOPYRANOSYL)-4-METHYL-3-[5-(4-FLUOROPHENYL)-2-THIENYLMETHYL]BENZENE AND PREPARATION METHOD THEREOF

SHANGHAI DESANO PHARMACEU...

1. A crystalline form W of 1-(?-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene, wherein the crystalline form W has an X-ray powder diffraction pattern substantially as shown in FIG. 1.
US Pat. No. 10,167,307

PROCESS FOR EXTRACTION OF SAPONINS FROM AGRICULTURAL PRODUCTS

Minn-Dak Farmers Cooperat...

1. A process for extracting saponin from agricultural feedstocks, comprising:preparing an agricultural feedstock for saponin extraction from the agricultural feedstock;
introducing the prepared agricultural feedstock and water into a tank to form a feedstock water solution;
adjusting the pH of the feedstock water solution to extract a saponin solution in an extraction liquid form;
clarifying the extraction liquid form to remove any insoluble suspended solids from the saponin solution;
filtering the saponin solution with a microfiltration member to separate a clean filtrate and a concentrated saponin solution, such that a saponin level within the concentrated saponin solution is concentrated by about 2 to about 10 times as compared to the saponin level in the saponin solution;
adjusting a pH of the concentrated saponin solution through the addition of an acid such that the pH of an acidified concentrated saponin solution is within a pH range from about 2 to about 7;
centrifuging the acidified concentrated saponin solution to separate suspended saponin solids from the acidified concentrated saponin solution thereby forming a suspended solid stream and a saponin-rich centrate; and
drying the suspended solid stream to form a purified saponin product.
US Pat. No. 10,166,283

NUCLEIC ACID COMPRISING OR CODING FOR A HISTONE STEM-LOOP AND A POLY(A) SEQUENCE OR A POLYADENYLATION SIGNAL FOR INCREASING THE EXPRESSION OF AN ENCODED PATHOGENIC ANTIGEN

1. A nucleic acid sequence comprising or coding fora) a coding region, encoding at least one peptide, wherein said peptide is not a histone peptide;
b) at least one histone stem-loop; and
c) a poly(A) sequence or polyadenylation signal;
wherein said peptide comprises a pathogen antigen or an antigenic fragment thereof, wherein the antigen is an antigen from a pathogen associated with infectious disease.
US Pat. No. 10,165,772

METHODS AND COMPOUNDS FOR INCREASING RED BLOOD CELL SURVIVAL

1. A blood or blood product storage kit comprising (a) a bag for ex vivo blood or blood product storage and (b) a conservation solution comprising from 10 ?M to 200 ?M of serotonin.
US Pat. No. 10,168,077

SELF-HEATING THERMAL INTERFACE MATERIAL

International Business Ma...

1. A self-heating thermal interface material (TIM), the self-heating TIM comprising:a TIM; andat least one heat producing component dispersed within the TIM, wherein the at least one heat producing component further comprises:at least one first microcapsule, the at least one first microcapsule having an outer shell, the outer shell forming a boundary between the TIM and contents of the at least one first microcapsule, the outer shell configured to sustain application of a compressive force without rupturing;
at least one first reactant and an at least one second reactant contained within the outer shell; and
at least one isolating structure within the outer shell, the at least one isolating structure preventing the at least one first reactant and the at least one second reactant from coming into contact when the compressive force is not applied, the at least one isolating structure configured to rupture when the compressive force is applied, the rupturing causing the at least one first reactant and the at least one second reactant to come into contact, the contact producing an exothermic reaction, the heat from the exothermic reaction transferring to the TIM.
US Pat. No. 10,166,285

RECOMBINANT VIRUS WITH DIMINISHED LATENCY AND METHODS OF USING SAME

1. A recombinant virus comprising all or a portion of a herpes virus genome, wherein a latency gene or its promoter is altered or modified so that the latency gene is overexpressed or has reduced expression, wherein the latency gene is a gene that corresponds to VZV ORF29 gene and encodes a major DNA binding protein, and wherein the virus has an impaired ability to establish latency and at least one of:the promoter is a heterologous promoter;
the latency gene is at a different location in the genome relative to its native location; or
a combination thereof.
US Pat. No. 10,168,334

IDENTIFICATION OF CANCER PROTEIN BIOMARKERS USING PROTEOMIC TECHNIQUES

Yale University, New Hav...

1. A method comprising:(a) measuring the expression level of proteins that consist essentially of prolactin, osteopontin (OPN), leptin, and at least one additional protein in a sample from a female subject, wherein the at least one additional protein is selected from macrophage migration inhibitory factor (MIF), insulin-like growth factor (IGF-II), 6Ckine, angiotensin converting enzyme (ACE), brain-derived neurotrophic factor (BDNF), E-Selectin, epidermal growth factor (EGF), eotaxin-2 (Eot-2), epidermal growth factor receptor 1 (ErbB 1), follistatin, hemofiltrate CC chemokine 4 (HCC4), herpes virus entry mediator (HVEM), insulin-like growth factor binding protein 2 (IGFBP-2), interleukin-17 (IL-17), interleukin 1 soluble receptor II (IL-1sRII), interleukin 2 soluble receptor alpha (IL-2 sR?), macrophage colony stimulating factor receptor (M-CSF R), macrophage inflammatory protein 1alpha (MIP-1?), macrophage inflammatory protein 3 beta (MIP3?), matrix Metalloproteinase-8(MMP-8), matrix metalloproteinase 7 (MMP-7), myeloid progenitor inhibitory factor 1 (MPIF-1), pulmonary and activation-regulated chemokine (PARC), platelet-derived growth factor receptor beta (PDGF R ?), protein C, tumor necrosis factor receptor 1 (TNF-RI), tumor necrosis factor alpha (TNF-?), soluble Vascular Adhesion Protein-1(sVAP-1), vascular endothelial growth factor receptor 2 (VEGF R2), VEGF receptor 3 (VEGF R3), human stratum corneum chymotryptic enzyme (HSCCE), kallikrein 4, kallikrein 5, kallikrein 6 (protease M), kallikrein 8, kallikrein 9, kallikrein 10, cancer antigen 125 (CA 125), CA15-3, CA19-9, OVX1, lysophosphatidic acid (LPA), carcinoembryonic antigen (CEA), macrophage colony-stimulating factor (M-CSF), prostasin, CA54-61, CA72, HMFG2, interleukin-6 (IL-6), interleukin-10 (IL-10), LSA, NB70K, PLAP, TAG72, TPA, UGTF, WAP four-disulfide core domain 2 (HE4), matrix metalloprotease 2, tetranectin, inhibin, mesothelin, MUC1, vascular endothelial growth factor (VEGF), NOTCH3, E2F transcription factor 3 (E2F3), GTPase activating protein (RACGAP1), hemotological and neurological expressed 1 (HN1), apolipoprotein A1, laminin, claudin 3 (CLDN3), claudin 4, tumor-associated calcium signal transducer 1 (TROP-1/Ep-CAM), tumor-associated calcium signal transducer 2 (TROP-2), ladinin 1, S100A2, SERPIN2 (PAI-2), CD24, lipocalin 2, matriptase (TADG-15), stratifin, transforming growth factor-beta receptor III (TGF-?-RIII), platelet-derived growth factor receptor alpha, SEMACAP3, ras homology gene family member I (ARHI), thrombospondin 2, disabled-2/differentially expressed in ovarian carcinoma 2 (Dab2/DOC2), and haptoglobin-alpha subunit in the sample from the subject;
(b) comparing the expression level of each of the measured proteins to a reference sample for each of the measured proteins; and
(c) determining if there is a significant difference in the expression level of each of the measured proteins in the sample as compared to the reference sample.
US Pat. No. 10,165,774

DEFOAMER USEFUL IN A PERACID COMPOSITION WITH ANIONIC SURFACTANTS

Ecolab USA Inc., Saint P...

1. A low-foaming equilibrium peracid composition comprising:a C1-C22 peroxycarboxylic acid;
a C1-C22 carboxylic acid;
hydrogen peroxide;
a mineral acid;
an anionic surfactant; and
from about 0.6 wt-% to about 0.75 wt-% of a metal salt defoaming agent, wherein the defoaming agent is aluminum sulfate;
wherein the composition has a use solution pH below about 4;
wherein the composition is provided as a concentrate, and wherein the composition is subsequently diluted at a ratio of between about 1:100 and about 1:5,000.
US Pat. No. 10,166,286

MIXED ALLERGEN COMPOSITIONS AND METHODS FOR USING THE SAME

The Board of Trustees of ...

1. A method of treating an autoimmune disease or inflammatory disease in a human subject in need thereof, the method comprising administering to the subject a mixed allergen composition comprising:2 to 20 different flours or powders, wherein at least one flour or powder is a nut flour selected from the group consisting of peanut, almond, walnut, cashew, hazelnut, pecan, and pistachio, at least one flour or powder is an animal powder selected from the group consisting of shrimp, cod, and salmon, and the mixed allergen composition comprises equal parts by protein weight of each flour or powder; and optionally
a vitamin selected from the group consisting of vitamin D and vitamin C;
wherein the composition is administered to the subject at least weekly or at least every other week.
US Pat. No. 10,167,312

METHOD OF TREATING MELANOCORTIN-4 RECEPTOR-ASSOCIATED DISORDERS IN HETEROZYGOUS CARRIERS

RHYTHM PHARMACEUTICALS, I...

1. A method for treating obesity or a metabolic syndrome in a subject in need thereof, wherein the method comprises administering to said subject an effective amount of Ac-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2 (SEQ ID NO: 140) or a pharmaceutically acceptable salt thereof, wherein the subject is a heterozygous carrier of an MC4R mutation.
US Pat. No. 10,168,337

METHOD AND BIOMARKERS FOR THE DETECTION OF DENGUE HEMORRHAGIC FEVER

THE BOARD OF REGENTS OF T...

1. A method for treating a subject having a dengue virus infection comprising:(a) measuring levels of (i) high molecular weight albumin, (ii) complement factor D and (iii) complement factor H; and determining a ratio of complement factor D to complement factor H (FactorD/FactorH) in a serum sample from the subject;
(b) measuring levels of IL2, desmoplakin, or IL2 and desmoplakin in a serum sample from the subject;
(c) determining with an accuracy of at least 90% by multivariate adaptive regression splines (MARS) classifier if the subject is at risk of developing dengue hemorrhagic fever (DHF) based on (i) the levels of high molecular weight albumin, (ii) the FactorD / FactorH ratio, and (iii) the levels of desmoplakin, or the levels of desmoplakin and IL2; and
(d) treating the subject with intensive supportive care if the subject is determined to be at risk of developing DHF.
US Pat. No. 10,166,289

COMPOSITIONS INCLUDING BETA-GLUCANS AND METHOD OF USE

Biothera, Inc., Eagan, M...

1. A method comprising:administering to a subject a first composition that comprises a yeast-derived soluble ?-glucan; and
administering to the subject a second composition that comprises a TLR agonist component, which is administered subsequent to the first composition;
wherein each of the first composition and second composition is in an amount that, in combination with the other, is effective to increase the subject's immune response to an antigen.
US Pat. No. 10,165,778

METHOD FOR CONTROLLING PESTS IN SOYBEAN

BASF SE, Ludwigshafen (D...

1. A method for controlling pests from the family of Pentatomidae and/or Thripidae, comprising contacting the pests, their food supply, habitat and/or breeding ground with one or more components of the ginkgo tree selected from the group consisting of bilobalide, ginkgolide A, ginkgolide B, ginkgolide C, ginkgolide J and ginkgolide M.
US Pat. No. 10,166,290

INTRALESIONAL (INTRATUMORAL) DINITROCHLOROBENZENE AND ASSOCIATED COMPOUNDS COADMINISTERED WITH CHECKPOINT INHIBITORS FOR CANCER TREATMENT INCLUDING TREATMENT OF METASTATIC CUTANEOUS CANCERS

1. A method of treating a primary or recurrent cancerous nodule or nodules in a subject comprising administering an intralesional injection of compounds including dinitrohalogenated benzene in association with the use of previous, subsequent, or simultaneous administration of a checkpoint inhibitor selected from the group consisting of ipilimumab, pembrolizumab, nivolumab and tremelimumab.
US Pat. No. 10,166,803

RECORDING MEDIUM

Canon Kabushiki Kaisha, ...

1. A recording medium comprising:a substrate; and
an ink-receiving layer provided on the substrate,
wherein the ink-receiving layer comprises a silica particle and a water-insoluble resin, and
wherein the silica particle satisfies the following expressions 1 and 2 when an average pore radius thereof determined by the BJH method is taken as r (nm), and an oil absorption thereof measured by the linseed oil droplet method is taken as V (ml/100 g):
r?5.0 (nm); and  expression 1:
V/r?80 ((ml/100 g)/nm).  expression 2:
US Pat. No. 10,165,780

METHODS AND COMPOSITIONS FOR TREATING POLLUTION

Aqua Dynamic Solutions, L...

1. A water treatment puck comprising:a. an oxidative alkali in a concentration from 30 to 50 percent by weight of the puck;
b. a clarifying agent comprising a dry powdered form of an activated botanical protein obtained from drumstick tree seed material (genus Moringa) in a concentration from 5 to 20 percent by weight of the puck; and
c. a dry powdered form of a Ricinus seed extract in a concentration from 0.5 to 20 percent by weight of the puck,
wherein the puck is a compressed homogenous mixture.
US Pat. No. 10,166,292

BLOCKING IL-9 SIGNALING IN CONJUNCTION WITH CHEMOTHERAPY TO TREAT CANCER

Mayo Foundation for Medic...

1. A method for treating a mammal having colon or breast cancer, wherein said method comprises administering a therapeutically effective amount of an inhibitor of IL-9 signaling alone to said mammal, wherein said inhibitor is an anti-IL-9 antibody, and wherein the progression of said colon or breast cancer or the number of colon or breast cancer cells within said mammal is reduced.
US Pat. No. 10,165,781

COMPOSITIONS AND METHODS USEFUL FOR THE PREVENTION OF MALARIA AND DENGUE VIRUS TRANSMISSION

The Johns Hopkins Univers...

1. A method for controlling malaria and dengue virus transmission via mosquitoes comprising applying in an area where the mosquitoes are to be controlled a composition comprising mosquito nectar feed and Chromobacterium sp_Panamam (Csp_P).
US Pat. No. 10,167,321

CYTOMEGALOVIRUS ANTIGENS AND USES THEREOF

GLAXOSMITHKLINE BIOLOGICA...

1. A recombinant Human Cytomegalovirus (HCMV) gL protein, or a complex-forming fragment thereof, wherein said gL protein or fragment comprises a mutation at Protease Recognition Site residues 91-102 numbered according to SEQ ID NO: 1, wherein said mutation reduces protease cleavage at said Protease Recognition Site as compared to a control.
US Pat. No. 10,166,297

ISOLATION OF NOVEL AAV'S AND USES THEREOF

University of Massachuset...

1. A method for delivering a transgene to a target tissue in a subject, the method comprising administering to the subject a recombinant adeno-associated virus (rAAV) that transduces cells of the target tissue and a transgene, wherein the transgene is engineered to express an RNA transcript that comprises at least one binding site for a miRNA that is expressed in cells of an off-target tissue of the subject, wherein the at least one miRNA binding site is positioned in the 5?UTR or 3?UTR of the RNA transcript, wherein the transgene comprises a tissue-specific promoter selected from a thyroxin binding globulin (TBG) promoter, insulin promoter, glucagon promoter, somatostatin promoter, pancreatic polypeptide (PPY) promoter, synapsin-1 (Syn) promoter, creatine kinase (MCK) promoter, mammalian desmin (DES) promoter, ?-myosin heavy chain (?-MHC) promoter, and a cardiac Troponin T (cTnT) promoter, and wherein the rAAV comprises a capsid protein from an AAV serotype selected from AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV10, AAV11, or AAV12.
US Pat. No. 10,165,788

METHODS AND COMPOSITIONS FOR IMPROVED DIGESTION OF MILK OLIGOSACCHARIDES

THE REGENTS OF THE UNIVER...

1. A method for promoting growth of beneficial gut bacteria in an individual having fucosylated oligosaccharides in the gut, comprising administering to the individual a composition comprising the beneficial gut bacteria, wherein the beneficial gut bacteria express a GH-29 family alpha-fucosidase and a GH-95 family alpha-fucosidase, wherein the beneficial gut bacteria are selected from B. adolescentis, B. catenulatum, B. pseudocatenulatum, B. dentium, and B. breve, thereby promoting growth of beneficial gut bacteria in the individual.
US Pat. No. 10,167,327

THERAPEUTIC USES OF MODIFIED FGF-21 POLYPEPTIDES

BRISTOL-MYERS SQUIBB COMP...

1. A method of decreasing or inhibiting fibrosis in a patient in need thereof, comprising administering to the patient an effective amount of a modified FGF-21 polypeptide comprising a polypeptide having at least 96% amino acid sequence identity to the amino acid sequence of SEQ ID NO: 202.
US Pat. No. 10,166,304

ANTIBODY FRAGMENTS FOR DETECTING CANCER AND METHODS OF USE

Regents of the University...

1. An immune reagent comprising a first scFv antibody fragment that specifically binds to membrane protein HSPG2 (Perlecan), wherein the first scFv antibody fragment is Clone-6 (SEQ ID NO:2).
US Pat. No. 10,168,611

MASK WITH MULTILAYER STRUCTURE AND MANUFACTURING METHOD BY USING THE SAME

TAIWAN SEMICONDUCTOR MANU...

1. A structure, comprising:a first layer;
a second layer disposed over the first layer;
a third layer disposed over the second layer; and
a fourth layer disposed over the third layer;
wherein:
the first layer, the second layer, the third layer, and the fourth layer are layers of a reflective structure of a lithography mask;
the first layer and the second layer combined have a first thickness;
the third layer and the fourth layer combined have a second thickness that is different from the first thickness;
the first layer and the third layer have a first material composition; and
the second layer and the fourth layer have a second material composition different from the first material composition.
US Pat. No. 10,167,334

TREATMENT OF CANCER USING ANTI-TGF-BETA AND PD-1 ANTIBODIES

XOMA TECHNOLOGY LTD., Be...

1. A method for treating cancer or reducing the recurrence of cancer comprising administering to a subject having cancer or who has had cancer, in therapeutically effective amounts, an inhibitor of transforming growth factor beta (TGF?) and an inhibitor of Programmed cell death protein 1 (PD-1), wherein the PD-1 inhibitor is an anti-PD-1 antibody; andwherein the TGF? inhibitor is an antibody that binds TGF? comprising:
a) a heavy chain CDR1 amino acid sequence set forth in SEQ ID NO: 19;
b) a heavy chain CDR2 amino acid sequence set forth in SEQ ID NO: 20;
c) a heavy chain CDR3 amino acid sequence set forth in SEQ ID NO: 21;
d) a light chain CDR1 amino acid sequence set forth in SEQ ID NO: 22;
e) a light chain CDR2 amino acid sequence set forth in SEQ ID NO: 23; and
f) a light chain CDR3 amino acid sequence set forth in SEQ ID NO: 24.
US Pat. No. 10,167,336

METHODS AND MATERIALS FOR TREATING CANCER

Mayo Foundation for Medic...

1. A method for exerting anti-cancer effects in a mammal having cancer, wherein said method comprises:(a) identifying said mammal as having an elevated level of PD-1+/CD11ahigh CD8 T cells within a T cell-containing sample; relative to a reference level of PD-1+/CD11ahigh CD8 T cells in mammals without cancer; and
(b) administering a PD-1 inhibitor to said mammal under conditions wherein naturally occurring tumor-reactive CD8 CTLs within a PD-1+/CD11ahigh CD8 T cell population of said mammal exert said anti-cancer effects against said cancer.
US Pat. No. 10,167,592

COMPOSITION FOR FIBER ADHESION AND FABRICS USING THE SAME

DOMAC LLC., Sejong (KR)

5. An article comprising a fabric manufactured by weaving a coated yarn comprising a yarn selected from polyolefin fiber, polyester fiber, nylon fiber, polyvinyl chloride fiber, polyurethane fiber, glass fiber or carbon fiber; and a coating layer, which comprises a fiber adhesion composition, the fiber adhesion composition comprising a thermoplastic resin, a titanium dioxide, a flame retardant, an ultraviolet absorber, and a heat stabilizer, wherein the fabric has a solar reflectance of 70% or more, a visible light reflectance of 80% or more, a solar transmittance of 15% or less, a visible light transmittance of 10% or less and a UV transmittance of 5% or less, wherein the article is a blind or light-shielding film.
US Pat. No. 10,166,314

REGENERATIVE PROSTHESES AS ALTERNATIVES TO DONOR CORNEAS FOR TRANSPLANTATION

UAB Ferentis, Vilnius (L...

1. A corneal implant having a first surface and a second surface, the corneal implant comprising:a matrix part containing a matrix material including a hydrogel of at least one first polymer and at least one second polymer, the first polymer including collagen or collagen mimetic peptide (CMP) provided with methacrylate or acrylate functional groups, the second polymer including a synthetic or a natural polymer having functional groups selected from thiol, acrylate or methacrylate, and the first and second polymers are cross-linked via said functional groups; and
a core part in a central part of the matrix material, the core part including a core material of an interpenetrating network (IPN), the IPN including polymerized olefinic monomers, UV polymerizable monomers or a mixture thereof and the hydrogel of the matrix material, the core material exposed at the first surface and at the second surface, the core part being transparent such that the core part has a light transmission of at least 80% within a wavelength range of 400 nm to 700 nm, the core part being anti-fouling, the core part configured to block or hinder cell migration and vessel ingrowth.
US Pat. No. 10,167,342

PRODUCTION OF HERSINTUZUMAB: A NEW HUMANIZED ANTIBODY AGAINST HER2 FOR CANCER TREATMENT

1. A humanized monoclonal anti-HER2 antibody for treating cancer, comprising:CDR-H1 comprising amino acid residues of 31-35 of SEQ ID NO: 1;
CDR-H2 comprising amino acid residues of 50-65 of SEQ ID NO: 1;
CDR-H3 comprising amino acid residues of 98-105 of SEQ ID NO: 1;
CDR-L1 comprising amino acid residues of 24-34 of SEQ ID NO: 5;
CDR-L2 comprising amino acid residues of 50-56 of SEQ ID NO: 5; and
CDR-L3 comprising amino acid residues of 89-97 of SEQ ID NO: 5.
US Pat. No. 10,167,343

ANTIBODIES AGAINST CD73

BRISTOL-MYERS SQUIBB COMP...

1. An isolated nucleic acid molecule encoding the heavy and light chains of an antibody which binds to human CD73, wherein the heavy and light chains respectively comprise:(a) heavy chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 5, 6, and 7, respectively, and light chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 9, 10, and 11, respectively;
(b) heavy chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 5, 6, and 7, respectively, and light chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 13, 14, and 15, respectively;
(c) heavy chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 17, 18, and 19, respectively, and light chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 21, 22, and 23, respectively;
(d) heavy chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 17, 18, and 19, respectively, and light chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 25, 26, and 27, respectively;
(e) heavy chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 17, 18, and 19, respectively, and light chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 29, 30, and 31, respectively;
(f) heavy chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 33, 34, and 35, respectively, and light chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 37, 38, and 39, respectively;
(g) heavy chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 41, 42, and 43, respectively, and light chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 45, 46, and 47, respectively;
(h) heavy chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 41, 42, and 43, respectively, and light chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 49, 50, and 51, respectively;
(i) heavy chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 53, 54, and 55, respectively, and light chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 57, 58, and 59, respectively;
(j) heavy chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 61, 62, and 63, respectively, and light chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 65, 66, and 67, respectively;
(k) heavy chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 69, 70, and 71, respectively, and light chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 73, 74, and 75, respectively;
(l) heavy chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 69, 70, and 71, respectively, and light chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 77, 78, and 79, respectively;
(m) heavy chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 81, 82, and 83, respectively, and light chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 85, 86, and 87, respectively; or
(n) heavy chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 89, 90, and 91, respectively, and light chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 93, 94, and 95, respectively.
US Pat. No. 10,167,345

ANTIGEN BINDING FORMATS FOR USE IN THERAPEUTIC TREATMENTS OR DIAGNOSTIC ASSAYS

1. A nucleic acid molecule encoding for an antigen binding format comprising:a first fusion protein wherein a CH1 constant domain of an antibody is fused i) by its N-terminal end to a C-terminal end of a first single domain antibody and ii) by its C-terminal end to an N-terminal end of a second single domain antibody, wherein the C-terminal end of the CH1 constant domain includes DKT which is fused directly to the N-terminal end of the second single domain antibody, and
a second fusion protein wherein a CL constant domain of an antibody is fused by its N-terminal end to a C-terminal end of a third single domain antibody, wherein said first, second and third single domain antibody may be the same or different, and wherein said CH1 constant domain and said CL constant domain are linked via a disulfide bond.
US Pat. No. 10,167,346

COMPOSITIONS AND METHODS FOR MAKING ALPHA-(1,2)-BRANCHED ALPHA-(1,6) OLIGODEXTRANS

1. A composition comprising an alpha-(1,2)-branched alpha-(1,6) oligodextran having alpha-(1,2)-osidic side chains, wherein said oligodextran comprises a backbone comprising alpha-D-glucopyranosyl units linked by alpha-(1,6)-linkages, wherein said alpha-(1,2)-osidic side chains are randomly distributed over the backbone, wherein said backbone has an average molecular weight between about 0.5 kDa and 40 kDa, wherein said backbone comprises at least 90% alpha-(1,6)-D-glucopyranosidic linkages; whereby the composition is useful for improving the health of a subject.
US Pat. No. 10,167,347

CARBOXYLATE ESTER OF POLYSACCHARIDE

BASF SE, Ludwigshafen (D...

1. A carboxylate ester of polysaccharide, wherein the polysaccharide is esterified with trimellitic anhydride and wherein a degree of substitution of the polysaccharide lies in the range of from 1 to 2.5.
US Pat. No. 10,168,630

TONER FOR DEVELOPING ELECTROSTATIC IMAGES

KONICA MINOLTA, INC., To...

1. A toner for developing electrostatic images, comprising toner particles containing an external additive on surfaces of toner matrix particles,wherein the external additive contains at least a lanthanum-containing titanate compound.
US Pat. No. 10,167,353

METHODS FOR INCREASING POLYMER PRODUCTION RATES WITH HALOGENATED HYDROCARBON COMPOUNDS

Chevron Phillips Chemical...

1. A process for producing an ethylene polymer at a target productivity, the process comprising:(a) contacting a metallocene-based catalyst system with ethylene and an optional ?-olefin comonomer in a polymerization reactor system under polymerization conditions; and
(b) controlling an amount of a halogenated hydrocarbon compound introduced into the polymerization reactor system to produce the ethylene polymer at the target productivity;
wherein the metallocene-based catalyst system comprises at least one metallocene compound.
US Pat. No. 10,167,356

FLUORINATED POLYMERS COMPRISING PHOSPHONIC MOIETIES

3M Innovative Properties ...

1. A polymer derived from(a) a fluorinated monomer comprising at least one of
(i) CnF(2n+1)(CH2)zOC(?O)CR?CH2 wherein n is an integer selected from 1 to 8, z is an integer selected from 1 to 20, and R is H or CH3; and
(ii) CnF(2n+1)SO2(NR?)(CH2)zOC(?O)CR?CH2 wherein n is an integer selected from 1 to 8; z is an integer selected from 3 to 20, and R is H or CH3 and R? is H or C1-C8 alkyl group, wherein the fluorinated monomer is selected from a group consisting of CF3CF2CF2CH2—O—C(?O)C(CH3)?CH2; and C8F17CH2CH2OC(?O)CH?CH2” after “alkyl group”; and
(b) a monomer comprising a phosphonic moiety, wherein the phosphonic moiety is selected from a group consisting of: —CH2?CHPO3H2, CH2?CHCH2PO3H2, and CH2?CHC(?O)O(CH2)2PO3H2.
US Pat. No. 10,167,870

CAN FOR MAGNETICALLY COUPLED PUMPS AND PRODUCTION PROCESS

1. A method for manufacturing a separating can (1), said method comprising the steps of:forming a flange part (4) of the can (1);
forming a bottom (2) of the can (1);
forming a side wall (3) arrangeable in a gap between a driver and a rotor of a magnetically coupled pump in a mounted condition of the can at least partially from a material comprising a nickel constituent, with the side wall (3) being brought by a reshaping step into a target geometry, said side wall having a reshaping degree of at least 10 percent, said side wall consisting at least partially of a material containing a nickel constituent, wherein the material is a nickel-chromium-iron alloy material in a solution annealed condition comprising between 50 and 55 percent by weight of nickel, between 17 and 21 percent by weight of chromium, between 10 and 25 percent by weight of iron, and between 0.5 and 10 percent by weight of niobium; further wherein said material has a deformation-free hardenability property; and
performing a hardening of said can after reshaping by a heat treatment; wherein said reshaping is a cold forming procedure and precipitation hardening is performed after cold forming.
US Pat. No. 10,165,823

DAMPING ELEMENT IN SHOE SOLES

BASF SE, Ludwigshafen (D...

1. A process for producing a shoe sole, the shoe sole comprising a hybrid material which comprises a polyurethane foam as a matrix material and an inlay component of expanded particles of a thermoplastic polyurethane;wherein the shoe sole does not comprise foamed particles of thermoplastic polyurethane in a region of at least 0.2 cm from an exterior edge of the shoe sole;
the process comprising:
preparing an inlay form by joining the expanded particles of a thermoplastic polyurethane in an amount and size of the desired inlay by placing them into a mould of the desired inlay size and joining them within the mould to obtain a prepared inlay form or by joining them in larger amounts to form large aggregates or sheets which are then cut to inlays of the desired size to obtain a prepared inlay form;
preparing the shoe sole by placing the prepared inlay form in a shoe sole mold such that an edge of the inlay form is 0.2 cm or more from an edge of the shoe sole mold;
embedding the inlay form within a reaction mixture in the shoe sole mold; and
reacting the reaction mixture to form the matrix in the shoe sole mold; obtain the shoe sole, and
removing the matrix with embedded inlay from the mold to obtain the shoe sole;
wherein the expanded particles of the inlay component are bonded with adhesives or with thermal adhesive bonding, and the reaction mixture comprises: a polyisocyanate; a compound having a hydrogen atom reactive toward isocyanate, and optionally at least one of a chain extender, a crosslinking agent, a catalyst, a blowing agent, and a further additive.
US Pat. No. 10,167,360

PROCESS TO PRODUCE POLYOLEFIN IONOMERS AND IONOMERS PRODUCED THEREBY

Dow Global Technologies L...

1. A process to produce an ionomer comprising:reacting alkyl-cis-cyclooctene and cis-cyclooctene in a mole ratio from 1:0.05 to 0.05:1, in the presence of a difunctional acid chain transfer agent under ring opening metathesis polymerization conditions to form an unsaturated polyolefin reactive telechelic pre-polymer;
hydrogenating the unsaturated polyolefin reactive telechelic pre-polymer to produce a hydrogenated polyolefin reactive telechelic pre-polymer;
reacting the hydrogenated polyolefin reactive telechelic pre-polymer with at least one compound according to the formula aMx+b(R)y, wherein M is a metal, x is a charge of M, R is an alkyl, aryl, oxide, or fatty acid, y is a charge of R, a and b are integers of at least 1, and ax+by=0, to form an ionomer.
US Pat. No. 10,167,361

PRODUCTION OF AROMATICS AND C2+OLEFINS

ExxonMobil Chemical Paten...

1. A process for producing aromatics and C2+ olefins, the process comprising:(a) providing a feed comprising syngas;
(b) reacting at least a portion of the syngas to produce an alcohol-containing mixture comprising C2+ alcohols and ?2 wt. % of methanol, wherein the C2+ alcohols include at least ethanol and propanol and wherein the alcohol-containing mixture comprises ?15 wt. % of ethanol, the weight percentages being based on the weight of the alcohol-containing mixture;
(c) separating a first stream and a second stream from the alcohol-containing mixture, wherein (i) the first stream comprises ?90.0 wt. % of the alcohol-containing mixture's methanol, based on the weight of the alcohol-containing mixture's methanol, (ii) the second stream comprises ?90.0 wt. % of the alcohol-containing mixture's C2+ alcohols, based on the weight of the alcohol-containing mixture's C2+ alcohols, and (iii) the second stream has a propanol:ethanol weight ratio in the range of from 0.1 to 0.5;
(d) reacting at least part of the first stream's methanol to produce a first hydrocarbon and a first oxygenate, the first hydrocarbon comprising ?25.0 wt. % of aromatics, ?1.0 wt. % of propylene, and ?50.0 wt. % of saturated hydrocarbons, the weight percentages being based on the weight of the first hydrocarbon; and
(e) reacting at least part of the second stream's C2+ alcohols to produce a second product comprising a second hydrocarbon and a second oxygenate, wherein (i) the second hydrocarbon comprises C2+ olefins, (ii) the second product comprises ?20.0 wt. % ethylene, based on the weight of the second product, (iii) the second hydrocarbon has a propylene: ethylene ratio in the range of from 0.30 to 0.40, and (iv) the reacting of the at least part of the second stream's C2+ alcohol comprises an oxygenate to olefin reaction.
US Pat. No. 10,167,364

PROCESS FOR PREPARING POLYCARBONATES BY TRANSESTERIFYING DITHIOCARBONATES OR SELENIUM ANALOGUES THEREOF WITH BISPHENOLS

COVESTRO DEUTSCHLAND AG, ...

1. A process for preparing polycarbonates, comprising reacting bisphenols with a transesterifying reagent in the presence of a catalyst, wherein the transesterifying reagent comprises a compound of the general formula (I):R—X—C(O)—X?—R?  (I)
wherein
X and X? are each independently S or Se, and
R and R? are each independently alkyl or aryl or
R and R? together are an alkylene chain.
US Pat. No. 10,166,088

UNIFIED THREE DIMENSIONAL VIRTUAL CRANIOFACIAL AND DENTITION MODEL AND USES THEREOF

Ora Metrix, Inc., Richar...

1. A method of registering an upper arch and a lower arch of a patient, with accompanying teeth with or without roots, with respect to jaw bones or facial tissue structure, comprising the steps of:capturing a three dimensional volumetric scan of a craniofacial complex and a dentofacial complex of the patient;
defining reference planes; and
registering (1) the three dimensional volumetric scan of the dentofacial complex with accompanying roots and (2) the patient's facial structure to the defined reference planes.
US Pat. No. 10,167,369

LIGHTFAST POLYURETHANE PREPREGS AND FIBER COMPOSITE ELEMENTS PRODUCED THEREFROM

Covestro Deutschland AG, ...

1. A prepreg consisting of a fiber layer saturated with polyurethane (matrix material) that has not been fully hardened and that has an NCO value of from 3% by weight to 17% by weight (DIN EN ISO 14896:2009-07-method A: method A=NCO value determined by titration), and that has a Tg-value below 40° C. (glass transition temperature Tg measured in accordance with DIN EN ISO 53765-A-20), wherein the polyurethane is a reaction product of a reaction mixture of:an isocyanate component consisting of:
A) one or more organic isocyanates selected from the group consisting of: unblocked aliphatic or cycloaliphatic di- and polyisocyanates, isocyanurates of unblocked aliphatic or cycloaliphatic di- and polyisocyanates, and combinations of any thereof;
and a polyol formulation consisting of:
B) a polyol component made of one or more polyols with a number-average OH number of from 30 to 1000 mg KOH/g, with a number-average functionality of from 1.9 to 2.5;
C) one or more dianhydrohexitols;
D) one or more latent catalysts which are catalytically active at temperatures of from 50° to 100° C.; and
E) optionally auxiliaries and/or additives, wherein component E) excludes polyepoxides,
wherein the initial viscosity directly measured after mixing of the reaction mixture at 40° C. is from 2300 to 3200 mPas (measured in accordance with DIN EN ISO 53019), and the ratio of the number of the NCO groups in component A) to the number of the OH groups in components B) and C) is from 1.3:1 to 10:1.
US Pat. No. 10,167,371

MEDICAL DEVICES HAVING ACTIVATED SURFACES

Covidien LP, Mansfield, ...

1. A polymeric medical device having an acid or base-treated surface that is functionalized with one or more click reactive members to provide an activated surface on the polymeric medical device.
US Pat. No. 10,170,704

ORGANIC ELECTROLUMINESCENT DEVICE AND DISPLAY INCLUDING THE SAME

SAMSUNG DISPLAY CO., LTD....

1. An organic electroluminescent device, comprising:a first electrode;
a hole transport region on the first electrode;
an emission layer on the hole transport region;
an electron transport region on the emission layer; and
a second electrode on the electron transport region,
wherein:
the electron transport region includes a first electron transport layer on the emission layer, and a second electron transport layer on the first electron transport layer,
an absolute value of difference between a highest occupied molecular orbital (HOMO) energy level of the emission layer and a HOMO energy level of the first electron transport layer is about 0.3 eV to about 1.5 eV,
the first electron transport layer includes a first electron transport material and a first n-type dopant, and
the second electron transport layer includes a second electron transport material and a second n-type dopant.